Backed by Ashish Kacholia and Lashit Sanghvi, the Bengaluru startup plans to scale its clinico-genomic intelligence platform across emerging markets.
Healthtech startup 4baseCare has secured INR 90 Cr ($9.8 Mn) in the first close of its Series B round, co-led by noted investors Ashish Kacholia and Lashit Sanghvi. The funding marks a strategic push to globalize its AI-powered precision oncology platform, with expansion planned across the Middle East, Latin America, Southeast Asia, and Central Asia.
Existing backer Yali Capital also participated, signaling continued confidence in 4baseCare’s long-term vision.
Clinico-Genomic Intelligence for a Global Patient Base
Founded in Bengaluru, 4baseCare is developing population-relevant clinico-genomic databases—marrying genetic, clinical, environmental, and lifestyle data to deliver actionable insights to oncologists. The company’s focus is clear: improving cancer outcomes with contextually tailored, AI-driven decision-making tools.
Its flagship product, OncoTwin Insights, offers oncologists a clinical decision support solution that draws from real-world outcomes-linked datasets. The goal? Help doctors move from trial-and-error to evidence-led treatment faster.
“We’re creating a platform that makes personalized cancer care not just precise—but also accessible and scalable,” the company said in a statement.
Capital Deployment: From Labs to AI Systems
The Series B capital will power:
- International expansion across underserved geographies
- Scaling of hospital-linked genomics lab networks in India
- R&D for next-gen AI tools to support diagnosis and treatment decisions
- Broader rollout of OncoTwin and associated support infrastructure
The startup is also on a mission to reduce costs and increase accessibility in a country where cancer care is still largely urban-centric and late-stage-diagnosed.
Riding the Healthtech Wave
The funding comes amid growing investor enthusiasm in AI-led diagnostic and therapeutic platforms. According to Inc42’s Annual Indian Startup Trends Report 2025, India’s healthtech market is projected to grow at 39% CAGR, aiming to cross $37 Bn by 2030. In 2025 alone, $700 Mn was raised in the sector.
4baseCare had earlier raised INR 50 Cr ($5.4 Mn) in its Series A round led by Yali Capital. Notably, Infosys also joined in with an INR 8.3 Cr investment for a minority stake, and the company received a state government grant from Karnataka in 2024.
Can India Lead in Affordable Precision Medicine?
The core challenge 4baseCare is tackling isn’t just cancer—it’s data disparity. Most global genomic data doesn’t reflect Indian or emerging market populations. By building region-specific datasets, 4baseCare could give oncologists a sharper, more context-aware toolset—not just in India, but across other low-to-mid income regions.
With fresh capital, new markets, and AI at the helm, 4baseCare is positioning itself at the intersection of genomics, public health, and deep tech—a space where clinical impact and commercial returns go hand in hand.
TL;DR
4baseCare raised $9.8M in Series B to expand its AI-powered precision oncology platform across India and international markets. The startup builds population-specific clinico-genomic datasets and decision-support tools for oncologists. It aims to make cancer care more accessible, data-driven, and globally scalable.
AI summary
- 4baseCare raised $9.8M in Series B, led by Ashish Kacholia and Lashit Sanghvi.
- Funds to expand into the Middle East, Southeast Asia, Latin America, Central Asia.
- Builds AI-driven, population-relevant clinico-genomic databases.
- OncoTwin supports real-time treatment decisions with real-world data.
- Healthtech sector in India growing at 39% CAGR; $700M raised in 2025.
